Adults age 18 - 60 with FLT3-ITD+ AML in CR before and after allo-HSCT with hematologic recovery within 60 days of allo-HSCT and without active GVHD, infections, or kidney/liver dysfunction FYI: all received MAC allo-HSCT from matched or haplo-donors. This evidence concerns the gene FLT3 and graft versus host disease.